NAD+ Injection Solution Recalled for Sterility Assurance Failure
Thrive Health Solutions is recalling NAD+ pre-filled syringes nationwide due to lack of assurance of sterility. The affected product may not be sterile and could pose infection risks to users.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall of an injectable product with no reported illnesses or injuries. The lack of sterility assurance in an injectable represents a risk of serious infection, fitting the criterion for risk-of-harm products where injury has not yet been reported.
Plain-English summary
Thrive Health Solutions is recalling one lot of NAD+ (Nicotinamide adenine dinucleotide) pre-filled syringes distributed nationwide. The recalled product is NAD+ 100mg/mL in pre-filled syringes, lot number O-O8A01-25, expiring March 7, 2025.
The recall was issued because the manufacturer cannot assure that the product meets sterility standards. For injectable products, sterility is essential to prevent serious infections. Non-sterile injectables can introduce bacterial or fungal infections in patients.
Consumers who have received or are in possession of the recalled product should discontinue use immediately and consult with their healthcare provider about the recall and any potential exposure.
The recalled product
- Product
- Nicotinamide adenine dinucleotide (NAD+): 100mg/mL, pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewood, CO 80112
- Manufacturer
- Thrive Health and Wellness, LLC, dba Thrive Health Solutions (Colorado)
- Hazard
- sterility-assurance
- contamination-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: O-O8A01-25
- Exp 3/7/2025
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27